Compare Amgen, Inc. (AMGN) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Vanguard Value Index Fund ETF — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Vanguard Value Index Fund ETF trades at $218.5. The key difference: Amgen, Inc. pays a 2.77% dividend while Vanguard Value Index Fund ETF pays none, and Vanguard Value Index Fund ETF is trading nearer its 52-week high, Amgen, Inc. nearer its low. Which is the better fit depends on your goals.
| AMGN | VTV | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | — |
52-Week High | $388.16 | $220.51 |
52-Week Low | $271.18 | $175.51 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
VTV (Vanguard Value ETF) trades at $219.20, up 0.29% with a bullish technical signal from moving averages. The ETF has gained 16% year-to-date and 27% over the past year, benefiting from investor rotation away from technology stocks toward value-oriented large caps. Recent news highlights VTV's defensive positioning with only 13% technology exposure and a focus on stable dividend-paying companies.
The outlook remains positive as value stocks continue their momentum amid AI sector concerns and potential Fed rate hikes. Key risks include macroeconomic sensitivity and sector rotation reversals. The ETF's low 0.03% expense ratio and higher dividend yield compared to broad market alternatives provide competitive advantages for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
